FRA1 Antibody

What is FRA1 and why is it important in research?

FRA1 (Fos-related antigen 1) is encoded by the FOSL1 gene and functions as a subunit of the AP-1 transcription factor complex. This protein plays crucial roles in cell proliferation, apoptosis, differentiation, inflammation, oncogenesis, and tumor metastasis . FRA1 has a canonical amino acid length of 271 residues and a protein mass of 29.4 kilodaltons, with two identified isoforms . It is primarily localized in the nucleus and is notably expressed in tonsil, stomach, small intestine, rectum, and kidney tissues . Research interest in FRA1 stems from its significant involvement in embryonic development, cancer progression, and immune regulation, making it a valuable target for studying cellular transformation and disease mechanisms .

How do I select the most appropriate FRA1 antibody for my experimental needs?

When selecting a FRA1 antibody, consider these methodological factors:

• Application compatibility: Determine whether the antibody has been validated for your intended application (WB, IHC, IF, ChIP, etc.) . For example, some antibodies perform better in Western blotting while others are optimized for immunohistochemistry.

• Species reactivity: Verify cross-reactivity with your species of interest. Many FRA1 antibodies react with human and mouse proteins, but reactivity varies among products .

• Epitope recognition: Consider which region of FRA1 the antibody targets. Some antibodies recognize specific domains that may be masked in certain experimental conditions or protein interactions .

• Antibody format: Determine whether a monoclonal or polyclonal antibody is better suited for your application. Monoclonal antibodies offer higher specificity but may recognize a single epitope that could be lost during processing, while polyclonals provide broader detection but potentially more background .

• Validation evidence: Examine the manufacturer's validation data, including images from relevant applications and cell lines similar to your experimental system .

What are the key differences between FRA1 and other AP-1 family members that could affect antibody selection?

When differentiating FRA1 from other AP-1 family members:

• Structural homology: FRA1 shares sequence similarity with other Fos family proteins (c-Fos, FosB, Fra-2), particularly in the DNA-binding and dimerization domains, which can lead to cross-reactivity in antibodies targeting these regions .

• Size distinction: FRA1 typically appears at approximately 40-45 kDa on Western blots, which differs from c-Fos (~62 kDa) and other family members, helping to confirm specificity .

• Post-translational modifications: FRA1 undergoes specific phosphorylation events that affect its stability and activity, which may influence antibody recognition depending on the cellular context and stimulation state .

• Expression patterns: Unlike some AP-1 factors that show ubiquitous expression, FRA1 displays tissue-specific expression patterns and is notably elevated in certain cancer types, which should be considered when selecting positive controls .

When selecting antibodies, use those specifically validated against FRA1 with demonstrated lack of cross-reactivity with other AP-1 family members, particularly in applications requiring high specificity such as ChIP experiments .

How should I optimize Western blot protocols when working with FRA1 antibodies?

For optimal Western blot detection of FRA1:

• Sample preparation: Extract nuclear proteins under denaturing conditions using buffers containing phosphatase inhibitors to preserve FRA1's phosphorylation state, which affects its mobility on SDS-PAGE .

• Loading control selection: Use nuclear protein markers (such as Lamin B) rather than cytoplasmic proteins (like GAPDH) as loading controls since FRA1 primarily localizes to the nucleus .

• Resolution considerations: Utilize 10-12% acrylamide gels to achieve optimal separation around the 40-45 kDa range where FRA1 migrates .

• Antibody dilution: Start with the manufacturer's recommended dilution (typically 1:1000 for Western blotting) and optimize as needed . For FRA1 detection, lower background is often achieved using overnight primary antibody incubation at 4°C.

• Signal verification: Be aware that some FRA1 antibodies may detect non-specific bands, including a reported 200 kDa protein of unknown identity in certain cell lines . Verify bands using positive controls with known FRA1 expression and consider using knockout/knockdown validation.

• Detection method: For detecting endogenous FRA1, which may be expressed at low levels in some cell types, enhanced chemiluminescence (ECL) systems with longer exposure times might be necessary .

What are the best practices for immunohistochemical detection of FRA1 in tissue samples?

For effective IHC detection of FRA1:

• Antigen retrieval: Implement heat-induced epitope retrieval using basic pH buffers (pH 9.0) to optimize FRA1 antigen accessibility, as demonstrated in successful protocols for human melanoma samples .

• Antibody concentration: Use higher concentrations than Western blotting (approximately 3 μg/mL for paraffin sections) to achieve adequate signal .

• Incubation conditions: Extend primary antibody incubation to overnight at 4°C to enhance sensitivity and specificity .

• Signal localization: Verify that positive staining is predominantly nuclear, which is consistent with FRA1's function as a transcription factor .

• Controls: Include both positive controls (tissues with known FRA1 expression such as melanoma or colorectal cancer samples) and negative controls (antibody diluent only) to validate staining specificity .

• Counterstaining: Use hematoxylin counterstaining to provide cellular context, allowing clear distinction between nuclear FRA1 staining and cytoplasmic background .

• Interpretation: Assess both staining intensity and percentage of positive cells, as FRA1 expression can be heterogeneous within tumors and may correlate with disease progression .

How can I effectively use FRA1 antibodies in Chromatin Immunoprecipitation (ChIP) experiments?

For successful ChIP experiments with FRA1 antibodies:

• Cross-linking optimization: Since FRA1 is a transcription factor that transiently binds DNA, optimize formaldehyde cross-linking time (typically 10-15 minutes) to capture these interactions without overfixing .

• Antibody selection: Choose ChIP-validated antibodies specifically, as not all FRA1 antibodies perform well in this application. The F2H9R rabbit monoclonal antibody has been validated for ChIP at a 1:100 dilution .

• Cell number: Use approximately 4 × 10^6 cells per immunoprecipitation to ensure sufficient chromatin material for FRA1 binding detection .

• Sonication parameters: Optimize sonication conditions to generate DNA fragments of 200-500 bp, which is optimal for detecting transcription factor binding sites.

• Controls: Include both a positive control (antibody against histone modifications) and negative controls (IgG and input samples) to assess enrichment specificity.

• Target validation: Design qPCR primers for known FRA1 binding sites, including AP-1 consensus sequences (TRE: TGA[G/C]TCA) in promoters of established target genes to validate ChIP efficacy .

• Sequential ChIP: Consider sequential ChIP (re-ChIP) approaches to investigate FRA1 interaction with other AP-1 components or cofactors, providing insight into complex-specific gene regulation .

How does FRA1 expression differ between human and rodent systems, and what implications does this have for research?

Understanding the human-rodent differences in FRA1 expression:

What are the most informative cellular models for studying FRA1 function using antibody-based techniques?

Optimal cellular models for FRA1 research include:

• Cancer cell lines with known FRA1 expression profiles:

  • A172 glioblastoma cells: Respond to EGF stimulation with increased FRA1 expression, useful for studying growth factor-induced FRA1 regulation

  • Melanoma cell lines: Express nuclear FRA1 and serve as excellent positive controls for antibody validation

  • Thyroid, breast, esophageal, and colorectal cancer cell lines: Show elevated FRA1 expression relevant to cancer progression studies

• Immortalized human fibroblast models:

  • TIG3 and BJ cells expressing hTERT and SV40 ER: Valuable for studying FRA1's transforming potential without the confounding effects of RAS oncogenes

  • HDF (human diploid fibroblasts): Useful for comparative studies of FRA1 induction between human and rodent cells

• Immune cell models:

  • Macrophage cell lines: Important for studying FRA1's role in cytokine production and innate immunity

  • T cell models (particularly Th17 cells): Critical for investigating FRA1's differential effects on human versus mouse immune cell differentiation

• Experimental considerations:

  • Stimulation protocols: EGF treatment (100 ng/mL for 18 hours) can induce FRA1 expression for dynamic studies

  • Subcellular localization: Nuclear extraction protocols are essential as FRA1 primarily localizes to the nucleus, though cytoplasmic retention has functional significance in some contexts

  • Genetic manipulation: CRISPR/Cas9 or siRNA knockdown of FRA1 provides important controls for antibody specificity validation

How can FRA1 antibodies be used to investigate the connection between FRA1 and immune regulation?

Antibody-based approaches to study FRA1 in immune regulation:

• Differential expression analysis:

  • Use Western blotting and immunohistochemistry to profile FRA1 expression across immune cell populations (T cells, B cells, macrophages, dendritic cells) under various inflammatory stimuli

  • Compare FRA1 expression in healthy versus diseased tissues (arthritis, pneumonia, psoriasis) to establish correlations with inflammatory states

• Cellular localization studies:

  • Employ immunofluorescence to track FRA1 nuclear-cytoplasmic shuttling, as cytoplasmic retention of FRA1 inhibits Type I interferon responses to malaria and viral infections

  • Use subcellular fractionation followed by Western blotting to quantify compartment-specific FRA1 levels after immune stimulation

• Protein-protein interaction analysis:

  • Utilize co-immunoprecipitation with FRA1 antibodies to identify immune-relevant binding partners in different cell types

  • Perform proximity ligation assays to visualize and quantify interactions between FRA1 and other immune regulators in situ

• Chromatin occupancy mapping:

  • Conduct ChIP-seq using FRA1 antibodies to identify genome-wide binding patterns at cytokine gene promoters containing AP-1 binding sites

  • Implement ChIP-qPCR to quantify FRA1 recruitment to specific immune-related gene promoters (IL-6, IL-1β, TNF-α) under various stimulation conditions

• Functional correlation studies:

  • Combine antibody-based detection of FRA1 with cytokine profiling to establish relationships between FRA1 levels and immune mediator production

  • Use phospho-specific FRA1 antibodies (if available) to track activation-dependent modifications that might regulate immune function

These approaches can help elucidate how Fra-1 differentially regulates IL-6 secretion in various disease models and cellular contexts, even within the same cell type .

How should I address non-specific bands or background issues when using FRA1 antibodies?

Strategies for improving specificity with FRA1 antibodies:

• Non-specific band identification:

  • Be aware that some FRA1 antibodies may detect a 200 kDa protein of unknown identity in certain cell lines

  • Distinguish specific FRA1 signal (approximately 40-45 kDa) from non-specific bands by running appropriate positive and negative controls

• Blocking optimization:

  • Test different blocking agents (5% BSA versus 5% non-fat dry milk) as FRA1 detection can be sensitive to blocking conditions

  • Extended blocking times (2 hours at room temperature) can reduce background in immunohistochemistry applications

• Antibody validation approaches:

  • Use genetic controls: Compare signals between wild-type and FRA1 knockdown/knockout samples to confirm band specificity

  • Peptide competition assays: Pre-incubate antibody with immunizing peptide to confirm specificity of detected bands

  • Multiple antibody verification: Employ antibodies targeting different FRA1 epitopes to confirm consistent detection patterns

• Protocol adjustments:

  • Increase washing duration and stringency (higher salt concentration or addition of 0.1% SDS to TBST) to reduce non-specific binding

  • For Western blotting, dilute antibody in the same buffer used for blocking to maintain consistent background reduction

  • For immunohistochemistry, implement additional peroxidase blocking steps to reduce endogenous peroxidase activity

• Signal optimization:

  • For weak signals, consider using signal enhancement systems rather than increasing antibody concentration, which can increase background

  • When possible, use fluorescent secondary antibodies for better signal-to-noise ratio in immunofluorescence applications

What are the critical controls needed when studying FRA1 expression in different experimental contexts?

Essential controls for FRA1 expression studies:

• Positive controls:

  • Cell lines with documented FRA1 expression: A172 glioblastoma cells (particularly after EGF stimulation), melanoma cells, and colorectal cancer cell lines

  • Tissue samples: Melanoma sections for IHC positive controls, tonsil, stomach, small intestine, rectum, and kidney tissues for normal expression patterns

  • Recombinant FRA1 protein: Can serve as a standard for antibody validation and sizing reference

• Negative controls:

  • FRA1 knockout or knockdown samples generated via CRISPR/Cas9 or siRNA technologies

  • Primary antibody omission controls in immunohistochemistry and immunofluorescence

  • Isotype controls for immunoprecipitation and ChIP experiments

• Treatment controls:

  • EGF stimulation (100 ng/mL for 18 hours) can be used as a positive induction control for FRA1 expression in responsive cell lines

  • Serum starvation followed by serum addition can help distinguish between basal and induced FRA1 expression

• Technical controls:

  • Loading controls: Nuclear markers (Lamin B) for FRA1 Western blotting given its nuclear localization

  • For ChIP experiments: Input samples, IgG controls, and positive control regions with known FRA1 binding

  • For qPCR analyses of FRA1 expression: Multiple reference genes to ensure accurate normalization

• Species-specific controls:

  • When comparing human and rodent systems, include both species' samples processed identically to account for species-specific differences in FRA1 regulation

How can I accurately interpret changes in FRA1 phosphorylation state using antibody-based techniques?

Methodologies for analyzing FRA1 phosphorylation:

• Phosphorylation detection strategies:

  • Mobility shift analysis: Phosphorylated FRA1 migrates more slowly on SDS-PAGE, appearing as higher molecular weight bands (45-47 kDa compared to unphosphorylated 40-43 kDa)

  • Phosphatase treatment controls: Treat parallel samples with lambda phosphatase to confirm that mobility shifts are due to phosphorylation

  • Phospho-specific antibodies: Though not widely available for all FRA1 phosphorylation sites, these would provide direct detection of specific modifications

• Sample preparation considerations:

  • Include phosphatase inhibitors (sodium orthovanadate, sodium fluoride, β-glycerophosphate) in lysis buffers to preserve phosphorylation states

  • Process samples quickly and maintain cold temperature throughout to minimize dephosphorylation

  • For highest resolution of phosphorylated species, consider using Phos-tag™ acrylamide gels that enhance separation of phosphorylated proteins

• Data interpretation guidelines:

  • Document both the intensity of FRA1 bands and their migration pattern to assess total expression versus phosphorylation changes

  • Consider that FRA1 stabilization often correlates with its phosphorylation status, affecting total protein levels

  • Relate phosphorylation changes to functional outcomes through parallel assays (e.g., transcriptional reporter assays for AP-1 activity)

• Contextual analysis:

  • FRA1 phosphorylation increases in response to various stimuli including growth factors, inflammatory signals, and stress

  • Phosphorylation protects FRA1 from proteosomal degradation, contributing to its accumulation during cell transformation

  • Different phosphorylation sites may have distinct functional consequences, requiring careful interpretation of mobility shifts

What emerging techniques are enhancing the study of FRA1 using antibody-based approaches?

Cutting-edge methods for FRA1 research:

• Single-cell technologies:

  • Single-cell Western blotting to analyze FRA1 expression heterogeneity within populations

  • CyTOF (mass cytometry) incorporating FRA1 antibodies for high-dimensional analysis of FRA1 in complex cell populations

  • Single-cell CUT&Tag for profiling FRA1 chromatin occupancy at single-cell resolution

• Proximity-based interaction mapping:

  • BioID or APEX2 proximity labeling fused to FRA1 to identify novel interacting partners in living cells

  • Proximity ligation assays (PLA) to visualize and quantify interactions between FRA1 and other transcription factors or regulatory proteins in situ

• Live-cell dynamics:

  • Developing FRA1 intrabodies (intracellular antibodies) to track FRA1 localization and dynamics in living cells

  • Antibody-based FRET sensors to monitor FRA1 conformational changes or interactions in real-time

• Spatial transcriptomics integration:

  • Combining immunohistochemistry for FRA1 with spatial transcriptomics to correlate FRA1 expression with gene expression patterns in tissue contexts

  • Multiplexed ion beam imaging (MIBI) or CODEX for highly multiplexed protein mapping including FRA1 and its targets

• Structural biology applications:

  • Using antibody fragments to stabilize FRA1 complexes for cryo-EM structural studies

  • Antibody-assisted crystallography to determine structures of FRA1 in complex with DNA or protein partners

How might understanding the role of FRA1 in immune regulation lead to new therapeutic approaches?

Therapeutic implications of FRA1 in immune regulation:

• Target identification in inflammatory diseases:

  • FRA1's role in regulating cytokine production (IL-6, IL-1β, TNF-α) suggests it could be targeted in inflammatory disorders such as arthritis, pneumonia, psoriasis, and cardiovascular disease

  • The differential effects of FRA1 on immune cell populations (e.g., Th17 cells) could be exploited to develop cell-specific interventions

• Cancer immunotherapy connections:

  • FRA1's dual role in cancer progression and immune regulation suggests targeting it might simultaneously affect tumor cells and the tumor microenvironment

  • Understanding how FRA1 regulates anti-tumor immune responses could improve immunotherapy outcomes, particularly in cancers with elevated FRA1 expression

• Biomarker development:

  • FRA1 expression or phosphorylation status might serve as biomarkers for inflammatory disease activity or immunotherapy responsiveness

  • Antibody-based assays could be developed for clinical assessment of FRA1 status in patient samples

• Drug development considerations:

  • Small molecule inhibitors disrupting FRA1 dimerization or DNA binding might be developed using antibody-based screening assays

  • Targeted protein degradation approaches (PROTACs) could be designed to selectively deplete FRA1 in specific contexts

• Delivery strategies:

  • Cell-penetrating antibodies or antibody fragments targeting FRA1 could be developed for research and therapeutic applications

  • Nanoparticle-based delivery of FRA1-targeting agents to specific immune cell populations could enhance therapeutic specificity

What are the most significant technical challenges remaining in FRA1 antibody-based research?

Persistent challenges in FRA1 antibody research:

• Isoform-specific detection:

  • Developing antibodies that can distinguish between the two identified FRA1 isoforms to study their potentially distinct functions

  • Creating tools to differentiate between splice variants or post-translationally modified forms in complex samples

• Phosphorylation site-specific antibodies:

  • Generating and validating antibodies against specific FRA1 phosphorylation sites to map kinase-specific regulation

  • Establishing standardized protocols for preserving and detecting labile phosphorylation events during sample processing

• Temporal dynamics:

  • Developing methods to capture rapid changes in FRA1 localization, modification, and complex formation in response to stimuli

  • Creating live-cell compatible antibody-based sensors to monitor FRA1 activity in real-time

• Complex-specific detection:

  • Designing approaches to selectively detect FRA1 in specific dimerization complexes (e.g., FRA1-JUN versus FRA1-ATF)

  • Developing conformational antibodies that recognize FRA1 only in active transcriptional complexes

• Quantitative analysis:

  • Establishing absolute quantification methods for FRA1 concentration in different cellular compartments

  • Developing standardized protocols for comparing FRA1 levels across different experimental systems and tissues

• Cross-species applications:

  • Creating antibodies with equivalent affinity and specificity across model organisms to facilitate translational research

  • Validating antibodies for conservation of epitopes between human and model organism FRA1 proteins